Amyotrophic lateral sclerosis and frontotemporal dementia

Deepen understanding of genetic causes

Recent, rapid advancements in the understanding of genetic causes of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) paved the way for development of gene-targeted genetic therapies tailored toward individual patients.1 Genetic testing to evaluate for the neurodegenerative conditions is an increasingly vital component in the diagnosis and management of individuals affected by ALS or FTD.

Frontotemporal dementia and ALS Test menu

Frontotemporal dementia and ALS

Our FTD and ALS evaluations include both targeted panels and single gene evaluations to confirm and clarify diagnosis. Using next-generation sequencing, our assays provide improved coverage, offering increased sensitivity at above 99% for single nucleotide variants, above 94% for deletions/insertions less than 40 base pairs (bp), and above 95% for deletions up to 75 bp and insertions up to 47 bp.

Key testing

  1. Roggenbuck J, Fong JC. Genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: impact on clinical management. Clin Lab Med. 2020;40(3):271-287. doi:10.1016/j.cll.2020.05.002

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.